Baraclude: profile and news
Novartis/Idenix: Entering Hepatitis B Market Feb 9, 2006
...therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol-Myers Squibb's Baraclude (entecavir), are able ... - International News Service,
Novartis/Idenix: entering hepatitis B market Feb 7, 2006
...therapies already available, namely GlaxoSmithKline's Zeffix, Gilead's Hepsera (adefovir dipivoxil) and Bristol-Myers Squibb's Baraclude (entecavir), are able ... - Pharmaceutical Business Review
Bristol-Myers Squibb Company Reports Financial Results for the ... Jan 25, 2006
...in 2004, primarily driven by increased investments in direct-to- consumer marketing campaigns for ABILIFY(R) and PLAVIX(R), the launch of BARACLUDE(TM), and ... - PR Newswire (press release),
Bristol-Myers Earnings Rise on Lower Costs; Sales Decline Jan 25, 2006
Quarterly sales were also helped by Baraclude, the hepatitis B treatment approved in March by the US Food and Drug Administration, and Erbitux, the cancer drug ... - Bloomberg
Bristol-Myers Net Rises on Lower Costs; Sales Drop (Update2) Jan 25, 2006
Total quarterly sales were helped by Baraclude, the hepatitis B treatment approved in March by the US Food and Drug Administration, and Erbitux, the cancer ... - Bloomberg
Bristol-Myers Net Rises on Lower Costs; Sales Drop (Update3) Jan 25, 2006
Total quarterly sales were helped by Baraclude, the hepatitis B treatment the FDA approved in March, and Erbitux, the cancer drug that Bristol-Myers sells with ... - Bloomberg
Tenofovir works as well for HBV in coinfected with 3TC resistance ... Jan 27, 2006
Currently, two other oral anti-HBV drugs are approved in the United States - adefovir (Hepsera) and entecavir (Baraclude) - although only adefovir currently ... - Aidsmap,
BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect ... Nov 14, 2005
...naive chronic hepatitis B adult patients (with wild-type virus) treated with the Bristol-Myers Squibb Company oral antiviral agent BARACLUDE(TM) (entecavir). ... - Finanzen.net,
Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection ... Nov 11, 2005
KK announced on November 10 that the Ministry of Health, Labor and Welfare has granted the company with a priority review status for BARACLUDE Tablet, an agent ... - Japan Corporate News (press release),
BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect ... Nov 14, 2005
Additional Study Data Presented at AASLD Investigated BARACLUDE Treatment Through 96 Weeks in Nucleoside-Naive HBeAg Positive Patients SAN FRANCISCO, Nov. ... - PR Newswire (press release),
China approves hepatitis B medicine Dec 2, 2005
US-based Bristol-Myers Squibb Co announced yesterday in the city that China's State Food and Drug Administration has approved Baraclude, an oral antiviral ... - Shanghai Daily,
Novartis: hepatitis B pill better than standard drug Nov 14, 2005
Bristol-Myers Squibb (BSY.N: Quote, Profile, Research) sells Baraclude for hepatitis B, which US health experts have said is more potent than either lamivudine ... - Reuters
(PRN) - Nam Tai Electronics, Inc.: New Monthly Sales Record of $80 ... Nov 14, 2005
...[+]. (PRN) - BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect Emergence of Resistance in Nucleoside-Naive Chronic Hepatitis B Patients ... [+. ... - Bolsamania.com,
Communications Media Announces Promotions Nov 15, 2005
...will assume a planning role for the Taro Pharmaceutical accounts and an assistant planner role for Bristol-Myers Squibb’s Orencia & Baraclude and NitroMed ... - PharmaLive.com (press release),
Idenix May Have 'Best-In-Class' Hepatitis Treatment Oct 4, 2005
..."Telbivudine will compete with Bristol-Myers Squibb's (nyse: BMY - news - people ) Baraclude, and today's Phase III data suggest the drug has the chance to be ... - Forbes
Hopes rise for Bristol-Myers Squibb Sep 12, 2005
Only two new drugs were cleared for US sales after 2001: the AIDS treatment Reyataz, approved in 2003, and Baraclude, a Hepatitis B medicine approved this year ... - Philadelphia Inquirer,
Fitch Affirms Bristol-Myers Squibb Co. 'A+'; Outlook to Stable Sep 16, 2005
...is supported by Bristol's R&D program which, in conjunction with its partners, has brought four drug products (Abilify, Reyataz, Erbitux, and Baraclude) to the ... - Business Wire (press release),
Bristol-Myers Ties Revival Hopes to 3 New Drugs (Update3) Sep 9, 2005
Only two new drugs were cleared for US sales after 2001 - -the AIDS treatment Reyataz, approved in 2003, and Baraclude, a hepatitis B medicine, approved ... - Bloomberg
Bristol-Myers Ties Revival Hopes to 3 New Drugs (Update3) 09 Sep 2005
Only two new drugs were cleared for US sales after 2001 - -the AIDS treatment Reyataz, approved in 2003, and Baraclude, a hepatitis B medicine, approved ... - Bloomberg
Potent drug vs hepatitis B introduced Sep 2, 2005
...announced that Indonesia has approved Baraclude (entecavir) for the treatment of chronic hepatitis B virus infection. An oral antiviral ... - INQ7 Interactive, Inc.,
